Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Rhea-AI Summary

Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to present at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. Replay available on company website.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 18, 2024 at the virtual B. Riley Securities 4^th Annual Oncology Conference: Tumor-ow’s Titans – Finding Value in (Near-) Commercial Oncology Companies.

For access to Mr. Auerbach’s live presentation at 2:00 p.m. ET on January 18, please contact your B. Riley representative. A replay of the presentation will be available on Puma’s website after 5:00 p.m. ET at https://www.pumabiotechnology.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111330386/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

What is the event Alan H. Auerbach will be presenting at?

Alan H. Auerbach will present at the B. Riley Securities 4th Annual Oncology Conference.

When will the presentation take place?

The live presentation will be at 2:00 p.m. ET on January 18, 2024.

Where can I access the replay of the presentation?

The replay will be available on Puma Biotechnology, Inc.'s website after 5:00 p.m. ET at https://www.pumabiotechnology.com.